INTRODUCTION
============

Arsenic (As) exposure is a major pandemic concern, with the number of arsenic-affected nations rising to seventy, including India, Bangladesh, Japan, China, USA, Argentina, Chile, Mexico, and Taiwan, among others ([@b1-tr-34-311]). In India, 7 states are reported to be affected by ground water arsenic contamination, and approximately 30 million individuals are consuming arsenic laden drinking water ([@b2-tr-34-311]). Chronic arsenic exposure is associated with several deleterious outcomes including cancers and death. Dermatological manifestations including raindrop hypopigmentation, hyper-pigmentation, palmo-palmer hyper-keratosis, Bowens disease (BD), basal cell carcinoma (BCC), and squamous cell carcinoma (SCC), which are considered hallmarks of chronic arsenic toxicity ([@b3-tr-34-311]). Interestingly, only 15--20% of individuals exposed to arsenic show arsenic-induced skin lesions ([@b2-tr-34-311]). This indicates that genetic variability and other underlying factors play an important role in arsenic susceptibility. Metabolism of arsenic within human cells utilizes several methyl moieties of S-adenosyl methionine (SAM) affecting the epigenetic profile of the genome in response to arsenic. In the presence of the arsenite-methyl transferase (As3MT) enzyme, the methyl group from SAM is transferred to inorganic arsenic. This enzyme-linked process generates reactive oxygen species (ROS) which contributes to several health outcomes including cancer of the liver, skin, lungs, and other internal organs. In addition, ROS induce genotoxic stress in the form of DNA damage, cell cycle arrest, and apoptosis ([@b4-tr-34-311],[@b5-tr-34-311]). Moreover, undulation in the epigenetic profile within DNA and histones alters the chromatin landscape within the cells. Epigenetic regulation by histone methylation has an important functional significance in chromatin compaction and contributes to the degree to which chromatin is present heterochromatin or euchromatin ([@b6-tr-34-311]). In our previous studies, we observed the impact of arsenic on promoter DNA-methylation pattern alteration. In another study we found that the tumor suppressor genes *p16* and death-associated protein kinase (*DAPK*) were downregulated due to promoter hypermethylation ([@b7-tr-34-311]). In addition, the interaction between excision repair cross-complementation group 2/Cdk-activating kinase complex (ERCC2/CAK) with transcription factor IIH (TFIIH) was inhibited by promoter hypomethylation of ERCC2, resulting in disruption of p53 phosphorylation, which impaired DNA damage recognition in arsenic exposed individuals ([@b8-tr-34-311]).

Biomarkers are extensively used in establishing and identifying biological effects of carcinogen exposure. Cytogenetic biomarkers such as chromosomal aberrations (CA), sister chromatid exchanges (SCE), or micronuclei formation (MN) are traditionally used for bio-monitoring genotoxic effects in humans ([@b9-tr-34-311]--[@b11-tr-34-311]). These cytogenetic endpoints are extensively used to identify the genotoxic potentials of toxic compounds and for cancer risk assessment. The micronuclei assay (MN assay) is a popular assay for evaluation of genotoxicity due to speed, ease of use of the technique, and lack of requirement of cells in metaphase. MN is a cytoplasmic inclusion within a cell (a miniature nucleus), which is formed by either a chromosomal break or due to lagging movement of any chromosome or chromatid during cytokinesis. Arsenic toxicity ROS production, which contributes to shearing of the phosphate backbone of nucleic acids, resulting in chromosomal breaks ([@b12-tr-34-311],[@b13-tr-34-311]). MN assay from three different cell types: peripheral lymphocytes, urothelial, and oral epithelial cells, are good predictors as biomarkers of genotoxicity ([@b14-tr-34-311]). Most studies that utilized MN assay were performed using urothelial cells ([@b13-tr-34-311]). Urinary bladder serves as an appropriate index to monitor the genotoxicity induced by arsenic because cells collected for the MN Assay are collected from the target tissue (the bladder) which should allow for more sensitivity in detecting arsenic effects ([@b15-tr-34-311]). In addition, cells from the urinary bladder are easy to collect. Moreover, MN in urothelial cells was ranked second based on review of 13 global studies ([@b13-tr-34-311]).

Recently, whether arsenic is a genotoxic carcinogen has been questioned ([@b16-tr-34-311]). In the trivalent methylated form, arsenic has been shown to be a potent genotoxic carcinogen that induces DNA damage, including chromosome breakage and numerical chromosome changes (aneuploidy). However, arsenic is not a point mutagen ([@b17-tr-34-311]). As arsenic is an exclusive human carcinogen, we have evaluated the existing literature on genotoxic effects of inorganic arsenic in multiple human test systems to determine the genotoxic potential of inorganic arsenic on human test systems both *in vitro* and *in vivo*. The goal of this review is to conclude whether inorganic arsenic is a genotoxic or nongenotoxic carcinogen.

GENOTOXIC POTENTIAL OF INORGANIC ARSENIC
========================================

Arsenic is non-mutagenic in nature as it lacks the ability to cause point mutations. However, the genotoxic potential of arsenic lies mainly with the ability to generate ROS ([@b18-tr-34-311]). ROS form various adducts with DNA and can also cause oxidative damage to the DNA backbone leading to breaks and subsequent CA and MN formation as observed in humans chronically exposed to arsenic ([@b19-tr-34-311]--[@b21-tr-34-311]). A study conducted in Mongolia with subjects chronically exposed to arsenic showed that expression of 8-oxoguanine DNA glycosylase (OGG1) was proportionally increased with increase in arsenic concentrations up to 149 μg/L (149 ppb). OGG1 is required for removal of 8OHdG implying that increased arsenic exposure leads to generation of 8OHdG in humans, necessitating increased expression of OGG1 ([@b22-tr-34-311]). A recent study comparing OGG1-deficient mouse embryonic fibroblast (MEF) cells with the wildtype cells revealed that OGG1 null cells are more inefficient in repairing the DNA damage than wildtype cells. Consequently, the OGG1 null cells over-expressed the arsenic metabolizing enzyme As3MT as an adaptive mechanism, conferring significant resistance to inorganic arsenicinduced cell death at the cost of accumulating high levels of DNA damage due to impaired repair. Accumulation of DNA damage may lead to carcinogenic outcomes of arsenic exposure ([@b23-tr-34-311]). Studies have reported arsenic-induced genotoxicity in humans exposed to chronic high doses of arsenic at levels much greater than the recommended WHO limit of 10 μg/L ([@b2-tr-34-311],[@b24-tr-34-311],[@b25-tr-34-311]). Recent studies have demonstrated that generation of ROS combined with reduced efficiency of DNA repair contributes to DNA damage resulting from arsenic, leading to observed genotoxic effects in humans ([@b8-tr-34-311],[@b26-tr-34-311]).

GENOTOXICITY STUDIES OF INORGANIC ARSENIC ON HUMAN CELLS *IN VITRO*
===================================================================

Recent *in vitro* studies analyzing the genotoxic potential of arsenicals using the conventional methods of CA, MN, SCE, and DNA damage in human cells are summarized in [Table 1](#t1-tr-34-311){ref-type="table"}. The *in vitro* studies listed used different forms of inorganic arsenic such as arsenate, arsenite, and arsenic trioxide. In a classic study, Petres *et al*. ([@b27-tr-34-311]) analyzed chromosomes of lymphocyte cultures from healthy people treated with sodium arsenate, and observed CA on par with patients who had been exposed to arsenic decades in the past ([@b27-tr-34-311]). Nakamuro and Sayato ([@b28-tr-34-311]) compared the cytogenetic effects of trivalent and pentavalent arsenic in cultured lymphocytes and fibroblasts. They found that CA induced by trivalent arsenic was significantly higher than by pentavalent arsenic. They also found that frequency of CA increased with increasing dose of both trivalent and pentavalent arsenicals. Vega *et al*. ([@b29-tr-34-311]) reported an aneugenic effect and CA induced by sodium arsenite in whole blood culture. They concluded that sodium arsenite induced dose-dependent aneuploidogenic effects and also induced significant CA *in vitro*. These results indicate that sodium arsenite causes mitotic arrest and aneuploidogenic effect. Similarly, aneuploidy-inducing effects of inorganic arsenic in cultured human lymphocytes treated with sodium arsenite showed a dose-dependent increase in CA over concentrations ranging from 0.001 to 0.1 μM. Sodium arsenite-treated cells from various donors exhibited similar CA frequencies ([@b30-tr-34-311]). They also investigated spindle formation using an anti-β-tubulin antibody which indicated that arsenite disrupts spindle formation by interacting with microtubules. Huang *et al*. ([@b31-tr-34-311]), investigated the effects of treatment with arsenicals during two different stages of growth. Post-treatment with sodium arsenite in the logarithmic growth phase in human lymphocytes treated with methanesulfonate synergistically increased CA in a dose-dependent manner. However, sodium arsenite treatment in stationary phase had no apparent effect on the clastogenicity of ethyl methanesulfonate treatment, which indicated that sodium arsenite has significant genotoxic properties. In 1995, Huang *et al*. performed similar experiments on cultured human fibroblasts, which demonstrated an inhibitory effect of arsenic on enzyme activity and significant CA. CA increased with sodium arsenite treatment in a dose-dependent manner ([@b32-tr-34-311]). Oya-Ohta *et al*. ([@b33-tr-34-311]) observed clastogenic effects of different arsenic compounds on cultured human fibroblasts. Both arsenite and arsenate induced significant CA in cultured human fibroblasts. These authors also concluded that glutathione (GSH) plays an important role in protecting against genotoxic effects of inorganic arsenic. Yih and Lee ([@b34-tr-34-311]) treated cultured human fibroblast cells with low dose arsenite for longer periods of time and high dose arsenite for shorter periods of time. In both cases, similar levels of arsenic accumulation were observed, but different levels of MN induction were observed. These results imply that oxidative stress induces micronuclei in human fibroblast cells. Jiang *et al*. ([@b35-tr-34-311]) compared the *in vitro* effects of sodium arsenite and arsenic trioxide on human lung adenocarcinoma A549 cells and found that both arsenicals caused cytotoxicity, DNA damage, and chromosomal breakage as measured by MN assay. They observed that genotoxic effects were much higher in arsenic trioxide versus sodium arsenite treated cells and concluded that these differential effects were due to their differential mechanisms to induce genotoxicity and anticancer effects. Hu *et al*. ([@b36-tr-34-311]) stated that both sodium arsenite and arsenic trioxide induced dose-dependent inhibition of colony formation, increased cellular apoptotic rate, increased reactive oxygen species levels, and increased MN frequency, with decreased cellular viability, colony formation rate, and GSH content in human hepatocyte L02 cells.

Several studies evaluated SCE to study genotoxicity of arsenic. Zanzoni and Jung ([@b37-tr-34-311]) evaluated SCE in metaphase in normal human lymphocytes after treatment with inorganic trivalent arsenic. They found a significant dose-dependent increase in SCE. Nordenson *et al*. ([@b38-tr-34-311]) investigated SCE in cultured lymphocytes after exposure to trivalent and pentavalent arsenic and observed that trivalent arsenic induced more significant SCE than pentavalent arsenic. Sodium arsenite induced a higher rate of SCE in Blackfoot disease patients consuming arsenic-contaminated water for more than fifteen years compared to healthy individuals drinking tap water ([@b39-tr-34-311]). This sodium arsenite dose-dependent increase in SCE resulted in delayed cell growth of lymphocytes. Crossen ([@b40-tr-34-311]) indicated that although arsenic induces SCE in human lymphocytes, dose-response to arsenic varies among individuals with regard to SCE. Sahu *et al*. ([@b41-tr-34-311]) demonstrated a significant increase in the frequencies of SCE in sodium arsenite-treated lymphocytes. When arsenite treated lymphocytes were exposed to UV rays, the increase in SCE did not reflect an additive effect of the two agents. In another study, induction of SCE and CA were measured in normal human lymphocytes treated with low concentrations of arsenite alone and arsenite in combination with the DNA cross linking agent diepoxybutane (DEB) ([@b42-tr-34-311]). Lymphocytes treated with arsenite concentrations as low as 1 μM displayed increased SCE frequencies, while CA frequencies were increased at 2 μM of arsenite. In the following year, Wiencke and Yager ([@b43-tr-34-311]) again concluded that arsenite specifically potentiates CA formation induced by DEB, but does not affect induction of SCE. These studies suggest a specific interaction of arsenite with induction or repair of DNA damage produced by DEB that leads to CA but not to SCE. Jha *et al*. ([@b44-tr-34-311]) performed a similar experiment in which human lymphocytes were treated with a combination of arsenite and X-rays. They found a dose-dependent response to arsenite treatment alone, whereas treatment with arsenite in combination with X-rays produced a synergistic effect. Hartmann and Speit ([@b45-tr-34-311]) compared the results of induction of SCE by arsenic on cultured human lymphocytes with DNA damage by single cell gel electrophoresis (comet assay). They found that arsenic concentrations that were toxic in the SCE test did not produce noticeable effects in the SCG assay, suggesting that the effects of arsenicals are not consistent for all genotoxicity assays. Rasmussen and Menzel ([@b46-tr-34-311]) compared the genotoxic effects of arsenite in lymphoblastoid cell lines and cultured human lymphocytes from a group of normal healthy volunteers exposed to sodium arsenite for 40 hr. SCE induction by arsenite was dose-dependent. Schaumloffel and Gebel ([@b47-tr-34-311]) found inorganic arsenic to be a more potent inducer of micronuclei than antimony in cultured human lymphocytes. Colognato *et al*. ([@b48-tr-34-311]) measured MN in cultured human lymphocytes challenged with trivalent and pentavalent arsenicals. They found that trivalent arsenicals showed more genotoxicity compared to pentavalent arsenicals. Avani and Rao ([@b49-tr-34-311]) treated peripheral blood lymphocyte cultures with a range of arsenic doses. Arsenic-treated cultures showed dose-dependent SCE. Interestingly, supplementation with vitamin A showed a remarkable protective effect against arsenic induced genotoxicity, mainly due to decreased oxidative stress resulting from free radical scavenging.

Several studies have demonstrated arsenic-induced DNA damage *in vitro*. Sordo *et al*. ([@b50-tr-34-311]) showed that sodium arsenite has cytotoxic effects by analyzing mitotic and replication indices in cultured blood lymphocytes, and demonstrated genotoxic effects by comet assay. They found organic arsenicals such as dimethylarsinic acid (DMA) and monomethylarsonic acid (MMA) had lesser DNA damaging properties than sodium arsenite. Guilamet *et al*. ([@b51-tr-34-311]) investigated possible DNA damage by three different inorganic and five different organic arsenic compounds in the TK6 human lymphoblastoid cell line using the alkaline comet assay. The results indicated that sodium arsenite was the only inorganic arsenic compound with genotoxic properties. Similarly, Yedjou and Tchounwou ([@b52-tr-34-311]) investigated genotoxicity of arsenic trioxide on the human leukemia cell line HL60 using comet assay. The results showed a dose-dependent increase in DNA damage, as evidenced by significant increases in comet tail length, tail arm, and tail moment. Stevens *et al*. ([@b53-tr-34-311]) performed a similar experiment with human colon cancer cells. They observed a dose-related increase in DNA tail length in cells treated with arsenic trioxide when compared to non-exposed cells. Human colorectal carcinoma cells treated with sodium arsenite also presented with increased micronuclei frequency, demonstrating a genotoxic effect ([@b54-tr-34-311]). Alarifi *et al*. ([@b55-tr-34-311]) stated that human hepatocellular carcinoma cells treated with arsenic trioxide showed significant reduction in enzymes related to oxidative stress after 24 and 48 hr of exposure. They also observed significant induction of DNA damage as measured by comet assay. Recently, Graham *et al*. ([@b56-tr-34-311]) performed an experiment with human induced pluripotent cells (IPS) and demonstrated a dose-dependent decrease in cell viability and increase in tail length and moment, in addition to destruction of intact DNA when exposed to arsenic trioxide. Xie *et al*. ([@b57-tr-34-311]) reported that human primary bronchial and epithelial cells *in vitro* exhibited a dose-dependent increase in genotoxicity as evidenced by chromosomal damage and DNA damage measured by Comet assay.

[Figs. 1](#f1-tr-34-311){ref-type="fig"}, [2](#f2-tr-34-311){ref-type="fig"} and [3](#f3-tr-34-311){ref-type="fig"} show analysis of dose-dependent genotoxic effects induced by arsenic using various genotoxic endpoints. The data are summarized using coefficients of determination (r^2^). The r^2^ values were calculated only from publications where full data were available. It is evident from [Table 1](#t1-tr-34-311){ref-type="table"} that, except for one publication, all studies demonstrated dose-dependent genotoxic effects induced by different species of inorganic arsenic. These results clearly indicate that inorganic arsenic is genotoxic in human cells *in vitro*.

GENOTOXICITY STUDIES OF INORGANIC ARSENIC ON HUMAN CELLS *IN VIVO*
==================================================================

[Table 2](#t2-tr-34-311){ref-type="table"} summarizes results of genotoxicity studies emphasizing CA, SCE, and MN performed in human populations. Few studies have measured DNA damage as a genotoxic parameter upon exposure to arsenic. Most of the studies summarized focused on human populations exposed to arsenic through drinking water. Ground water arsenic mainly contains the inorganic trivalent and pentavalent arsenic, with minor amounts of organic arsenic. As such, we considered reports of genotoxic effects in these studies to be mainly from inorganic arsenic sources such as arsenate and arsenite. Petres *et al*. ([@b58-tr-34-311]) analyzed CA in lymphocytes of a population exposed to arsenic through drinking water. They found an increased number of chromosome and chromatid structural anomalies, as well as increased aneuploidy rate, in the arsenic-exposed group. Nordenson *et al*. ([@b59-tr-34-311]) found increased frequency of CA in lymphocytes of psoriatic patients who were treated with arsenic, even more than 15 years after discontinuing therapy. Burgdorf *et al*. ([@b60-tr-34-311]) reported an increased SCE rate in lymphocytes of patients treated with arsenic in the form of potassium arsenite, indicating significant genotoxic potential of this arsenical. A pilot study on hydroarsenicism was carried out by Ostrosky Wegman *et al*. ([@b61-tr-34-311]) on an arsenic-exposed population in Mexico. The frequency of SCE and percentage of CA were similar in chronically exposed individuals and individuals who were less-exposed to arsenic. However complex aberrations were more frequent in the chronically exposed group. In another study, conducted by Vig *et al*. ([@b62-tr-34-311]) on humans of different ages and backgrounds who had been drinking contaminated water with more than 0.05 mg/L (0.05 ppm) arsenic for a minimum period of five years, no correlation was found between frequency of CA and SCE in lymphocytes and amount of arsenic in the water.

Copper smelters are potential sources of high arsenic pollution and many studies have been conducted among different copper smelters around the world. In the study conducted by Beckman *et al*. ([@b63-tr-34-311]) the occurrence of CAs in lymphocytes significantly increased among the smelter workers compared to control. Nordenson *et al*. ([@b64-tr-34-311]) found a significant interaction of smoking with arsenic exposure suggesting smoking can influence the genotoxic outcome of arsenic exposure. Another study conducted on smelter workers of Yunnan Tin Corporation in China found increased CA and MN frequency in cultured lymphocytes of arsenic-exposed participants, which was also associated with occurrence of lung cancer ([@b65-tr-34-311]). In another study by Nilsson *et al*. ([@b66-tr-34-311]) a significantly higher incidence of CA was found in hair and nail tissues in five women residing in an area heavily contaminated with inorganic arsenic from a copper smelter located in Bulgaria compared to controls. In Argentina, individuals who had been drinking arsenic-contaminated water (more than 0.13 mg/L) for a period not less than 20 years had significantly increased SCE compared to control ([@b67-tr-34-311]). A study in Nevada by Warner *et al*. ([@b68-tr-34-311]) stated that a distinct 1.8-fold increase with 90% confidence interval (1.06--2.99-fold) was observed in frequency of MN in bladder cells in the exposed group when compared with the unexposed group. They also stated that MN frequency in bladder cells was positively related to concentration of inorganic arsenic in urine. Dulout *et al*. ([@b69-tr-34-311]) studied the clastogenicity and aneugenicity of arsenic in women and children only. The population residing in Northwestern Argentina was exposed to high levels of arsenic (approximately 0.2 mg/L in drinking water. A similar ethnic group was evaluated with extremely low exposure to arsenic via drinking water from Rosario de Lerma, Salta. Genotoxic effects were evaluated by MN assay in binucleated cells and SCE in lymphocytes. This study found a significant increase in frequency of MN, but no specific change in SCE of the exposed group. Moore *et al*. ([@b70-tr-34-311]) found elevated occurrence of MN in exfoliated bladder cells in individuals chronically exposed to high levels of arsenic in Nevada when compared with matched controls. Frequencies of MN contain acentric fragments which results from chromosome breakage. In another cross-sectional biomarker study in a Chilean male population chronically exposed to arsenic (average concentration was 600 μg/L), the same research group observed elevated MN frequencies in bladder cells when compared to the low arsenic exposure (average concentration was 15 μg/L) group ([@b71-tr-34-311]). MN was detected by fluorescence *in situ* hybridization with a centromeric probe to detect the presence of whole chromosomes. They observed a dosedependent increase in MN with urine arsenic levels. The authors concluded that arsenic can induce genetic damage and that chromosome breakage is the main cause of MN formation ([@b71-tr-34-311]). Biggs *et al*. ([@b72-tr-34-311]) used the MN assay to evaluate exfoliated bladder cells of individuals exposed to arsenic through drinking water. They reported that bladder cell micronuclei correlated with arsenic exposure.

In Mexico, Gonsebatt *et al*. ([@b73-tr-34-311]) studied CA in blood lymphocytes and MN in epithelial cells obtained from oral mucosa and urine samples. A significant increase in frequency of MN in oral and urinary epithelial cells and chromatid and isochromatid deletions in lymphocytes were found in the arsenic-exposed group. They also found that individuals with skin lesions had more MN in oral cells. Mäki-Paakkanen *et al*. ([@b74-tr-34-311]) observed a significant increase in CA in lymphocytes of 42 individuals exposed to arsenic through well water with an arsenic concentration of 410 μg/L in Finland. Blackfoot disease is well-known for its association with consumption of arsenic containing well water. In a cytogenetic survey conducted by Liou *et al*. ([@b9-tr-34-311]) on 686 residents of three villages in a Blackfoot endemic area in Taiwan, 31 patients developed cancer during the 4 year follow up period. Twenty-two patients in the group that did not develop cancer were selected as controls, and 22 patients that developed cancer were selected as exposed group. The frequencies of chromosome-type aberrations were significantly higher in the exposed group than that of the control. There was no significant difference in SCE and chromatid type aberrations among the exposed and control groups. Other than CA and SCE, many studies have been performed to evaluate micronuclei formation in urothelial, buccal, or peripheral lymphocyte cells in all parts of the world. Tian *et al*. ([@b25-tr-34-311]) observed a significant increase in MN in buccal cells, bladder cells, and sputum cells of individuals exposed to high arsenic levels compared to those with low exposure from a population in Central West Inner Mongolia, China. Martínez *et al*. ([@b75-tr-34-311]) studied MN in human lymphocytes of individuals exposed to arsenic through drinking water and observed that the frequency of MN in the exposed group was significantly higher compared to the control group. In contrast, Martínez *et al*. ([@b76-tr-34-311]) found no association between frequency of MN in buccal cells and arsenic levels in drinking water. Ghosh *et al*. ([@b2-tr-34-311]) stated that higher levels of MN in oral mucosa and CA in lymphocytes were found in an arsenic exposed population. In the following year, Ghosh *et al*. ([@b11-tr-34-311]) showed greater levels of CA in lymphocytes of individuals with neoplastic skin diseases versus non-cancerous skin lesions in a population exposed to arsenic in well water. Sampayo Reyes *et al*. ([@b77-tr-34-311]) found a positive association in micronuclei and percentage of DNA damage evidenced by tail length using comet assay of urinary bladder cells and lymphocytes.

In West Bengal, India, arsenic is an epidemic in nine districts. In addition, Bangladesh is also associated with high levels of various clinical manifestations of chronic arsenicosis. Many studies have been conducted in arsenic contaminated areas of West Bengal. Mahata *et al*. ([@b78-tr-34-311]) conducted a bio-monitoring study using CA and SCE as end points to investigate the cytogenetic effects of chronic arsenic exposure in a population of 59 individuals residing in North 24 Parganas district. A significant increase in both CA and SCE were observed in the exposed group when compared to the control group. Basu *et al*. ([@b79-tr-34-311]) performed a similar experiment with a population from four affected districts of West Bengal, and found a statistically significant increase in frequency of MN in urothelial cells, oral mucosa, and lymphocytes when compared with controls. Two years later, Basu *et al*. ([@b14-tr-34-311]) again performed a biomarker study on 163 inhabitants of North 24 Parganas and compared them with 154 unexposed controls residing in the unaffected East Midnapur. They found significantly elevated levels of micronuclei frequencies in the exposed group: 5.33-fold versus control for lymphocytes, 4.63-fold for oral mucosa cells, and 4.71-fold for urothelial cells *p* \< 0.01). In the next year, the same group ([@b80-tr-34-311]) used alkaline comet assay to measure DNA damage in lymphocytes of 30 people exposed to high levels of arsenic in drinking water. The exposed individuals expressed a significant dose-dependent increase in DNA damage (*p* \< 0.01) in lymphocytes versus unexposed individuals.

Yanez *et al*. ([@b81-tr-34-311]) studied DNA damage by comet assay in lymphocytes of children lymphocytes Villa de la Paz, S.L.P. (Mexico), with control samples taken from children living in a less exposed town (Matehuala). The urinary concentration of arsenic in children of Villa de la Paz (geometric mean 136 μg/g creatinine) was significantly higher than in the control children living in Matehuala (34 μg/g creatinine). The results found by the comet assay showed that the tail length and the tail moment in the exposed children were significantly higher than those observed for control (*p* \< 0.05). In a study in Northern Chile, the relationship between arsenic occupational exposure and genotoxic effects in smelting plant workers was studied by Paiva *et al*. ([@b82-tr-34-311]). They did not find any significant differences in MN in lymphocytes of the occupationally-exposed population. The effect of chronic exposure of arsenic on occurrence of dermatological symptoms was investigated by Dastgiri *et al*. ([@b83-tr-34-311]) in a community in northwest Iran. The exposed group was from Ghopuz village (1,031 ± 1,103 μg/L of arsenic in drinking water) and the control from a Mayan village with no arsenic exposure. Hyperkeratosis observed in the exposed group was 34 times higher than that of the control subjects. They also found that 25% of the exposed group showed CA (*p* = 0.05). Bartolotta *et al*. ([@b84-tr-34-311]) evaluated micronuclei in exfoliated buccal cells of an arsenic-exposed group sampled from the rural population of Santiago del Estero and a control group consisting the urban population of Buenos Aires in Argentina. They found a significant (*p* = 0.0005) increase in number of micronuclei in the exposed group when compared to the control group. Banerjee *et al*. ([@b7-tr-34-311]) reported that arsenic from rice alone can induced genotoxicity in humans when water arsenic content was less than the permissible limit set by WHO. A significant increase in MN was observed in urothelial cells of individuals who consume rice as a staple when the rice contained arsenic at a concentration of more than 200 μg/kg of rice. They also observed a dose-related increase in MN with rice arsenic concentrations. Gamino-Guitarrez *et al*. ([@b85-tr-34-311]) carried out geochemical and health studies of children in urban areas of Villa de la Paz, S.L.P. (Mexico), where the surface has been contaminated with arsenic by mining activities for more than 200 years. They found that at least 20\~30% of children had urine arsenic levels higher than the maximum intervention values set nationally and internationally. MN assay in exfoliated bladder cells was significantly higher in children with high urine arsenic levels. Chatterjee *at al*. ([@b86-tr-34-311]) measured the frequency of MN in buccal mucosa, urothelial cells, and lymphocytes of children exposed to arsenic and compared it with buccal mucosa, urothelial, and lymphocyte cells of children from an unexposed area. They found all three cell types had significantly higher (*p* \< 0.0001) MN frequency in the arsenic exposed group compared to the unexposed group.

[Fig. 4](#f4-tr-34-311){ref-type="fig"} shows the analysis of dose-response effects by evaluating the r^2^ value from the data presented by the authors. Although almost all publications showed genotoxic effects of inorganic arsenic *in vivo*, only some authors have presented positive dose-response effects. As expected in the *in vivo* studies in humans, it is difficult to obtain dose-response effects. Although arsenic exposure through drinking water is the same, there are several reasons for not reporting dose-response effects, such as: a) variation in consumption of arsenic contaminated water by different individuals, b) dietary habits of the individuals, c) variation in the rate of arsenic excretion and d) age, tobacco use, alcohol consumption, malnutrition, etc. All of these factors may contribute to genotoxic effects *in vivo* and thus, most *in vivo* studies do not show any dose-response effects even if they were divided into different groups based on water or urine arsenic levels. However, it is important to note that almost all *in vivo* studies on humans showed positive genotoxic effects when compared to arsenic unexposed population.

CONCLUSIONS
===========

As per OECD guidelines, it is mandatory to include one *in vitro* test and one *in vivo* mammalian test to identify the genotoxic potential of the compound. If the compound shows genotoxic potential *in vitro* as measured by CA, MN, and DNA damage with evidence of dose-response effects and also genotoxic effects *in vivo* in a mammalian system, then, per OECD guidelines, we can consider that compound as a genotoxic agent. Interestingly inorganic arsenic demonstrates clear genotoxic effects on human cells *in vitro* with evidence of dose-response effects as described in this review. Similarly, almost all *in vivo* studies on inorganic arsenic also clearly show genotoxic effects in human systems. Since all *in vivo* results were obtained from human studies, the results may not show dose-response effects, an issue which have addressed in the text. Considering substantial global publications on genotoxic potential of inorganic arsenic on human cells *in vitro* and *in vivo*, we have no hesitation to conclude that inorganic arsenic is a genotoxic human carcinogen and not a non-genotoxic carcinogen.
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![*In vitro* dose dependent genotoxic effects of sodium arsenite as determined by (A) sister chromatid exchanges per chromosome, (B--D), sister chromatid exchanges per cell, (E) chromosomal aberrations per cell, (F--J) percentage of chromosomal aberrations, (K) frequency of micronuclei formation, and (L) frequency of micronucleated cells. Representative graphs are prepared based on data from various studies as indicated. Correlation between sodium arsenite concentrations and genetic damage was determined with a linear regression model.](tr-34-311f1){#f1-tr-34-311}

![*In vitro* dose dependent genotoxic effects of sodium arsenate as determined by (A, B) percentage of chromosomal aberrations and (C) frequency of micronucleated cells. Representative graphs are prepared based on data from various studies as indicated. Correlation between sodium arsenate concentrations and genetic damage was determined with a linear regression model.](tr-34-311f2){#f2-tr-34-311}

![*In vitro* dose dependent genotoxic effects of arsenic trioxide as determined by (A, B) sister chromatid exchanges per cell and (C) percentage of chromosomal aberrations. Representative graphs are prepared based on data from various studies as indicated. Correlation between arsenic trioxide concentrations and genetic damage was determined with a linear regression model.](tr-34-311f3){#f3-tr-34-311}

![*In vivo* dose dependent genotoxic effects of arsenic in humans exposed through various sources. Genotoxicity was estimated by (A, B) frequency of micronuclei formation, (C) frequency of micronucleated cells, and (D) comet length. Representative graphs are based on data from various studies as indicated. Correlation between arsenic concentrations and genetic damage was determined with a linear regression model.](tr-34-311f4){#f4-tr-34-311}
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Inorganic arsenic induced genotoxic effects on human cells *in vitro*

  Test systems                                                                              Arsenic species                                         End points                Effects   Dose response   References
  ----------------------------------------------------------------------------------------- ------------------------------------------------------- ------------------------- --------- --------------- ----------------------------------------------------
  Human lymphocytes                                                                         Sodium Arsenite                                         CA                        \+        \+              Petres *et al*. ([@b27-tr-34-311])
  Human lymphocytes                                                                         Sodium Arsenite and Sodium Arsenate                     SCE                       \+        \+              Zanzoni and Jung ([@b37-tr-34-311])
  Human lymphocytes                                                                         Sodium Arsenite and Sodium Arsenate                     CA                        \+        \+              Nordenson *et al*. ([@b38-tr-34-311])
  Human lymphocytes                                                                         Sodium Arsenite, Sodium Arsenate and Arsenic trioxide   CA                        \+        \+              Nakamuro and Sayoto ([@b28-tr-34-311])
  Human lymphocytes                                                                         Sodium Arsenite and Sodium Arsenate                     SCE                       \+        \+              Crossen ([@b40-tr-34-311])
  Human lymphocytes and Human fibroblast                                                    Sodium Arsenite                                         CA                        \+        \+              Huang *et al*. ([@b31-tr-34-311],[@b32-tr-34-311])
  Human lymphocytes                                                                         Sodium Arsenite                                         SCE                       \+        −               Sahu *et al*. ([@b41-tr-34-311])
  Human lymphocytes and fibroblast                                                          Sodium Arsenite                                         CA, SCE                   \+        \+              Jha *et al*. ([@b44-tr-34-311])
  Human lymphocytes                                                                         Sodium Arsenite                                         CA                        \+        \+              Wiencke and Yager ([@b42-tr-34-311])
  Human lymphocyte                                                                          Sodium Arsenite                                         SCE                       \+        \+              Yager and Wiencke ([@b43-tr-34-311])
  Human lymphocyte                                                                          Sodium Arsenite                                         SCE                       \+        \+              Hartmann and Speit ([@b45-tr-34-311])
  Human lymphocyte                                                                          Sodium Arsenite                                         CA                        \+        \+              Vega *et al*. ([@b29-tr-34-311])
  Human fibroblasts                                                                         Sodium Arsenite and Sodium Arsenate                     CA                        \+        \+              Oya-Ohta *et al*. ([@b33-tr-34-311])
  Human lymphocytes                                                                         Sodium Arsenite                                         CA                        \+        \+              Ramirez *et al*. ([@b30-tr-34-311])
  Human lymphocytes                                                                         Sodium Arsenite and Sodium Arsenate                     SCE                       \+        \+              Rasmussen and Menzel ([@b46-tr-34-311])
  Human lymphocytes                                                                         Sodium Arsenite                                         MN                        \+        \+              Schaumloffel and Gebel ([@b47-tr-34-311])
  Human fibroblasts                                                                         Sodium Arsenite                                         MN                        \+        \+              Yih and Lee ([@b34-tr-34-311])
  Human lymphocytes                                                                         Sodium Arsenate                                         DNA damage                \+        \+              Sordo *et al*. ([@b50-tr-34-311])
  TK6 human lymphoblastoid cells                                                            Sodium Arsenite and Sodium Arsenate                     DNA damage                \+        \+              Guillamet *et al*. ([@b51-tr-34-311])
  Human lymphocytes                                                                         Sodium Arsenite and Sodium Arsenate                     MN                        \+        \+              Colognato *et al*. ([@b48-tr-34-311])
  Human lymphocytes                                                                         Sodium Arsenite                                         SCE                       \+        \+              Avani and Rao ([@b49-tr-34-311])
  HL-60 (human promyelocytic leukemia) cells                                                Sodium Arsenite                                         DNA damage                \+        \+              Yedjou and Tchounwou ([@b52-tr-34-311])
  RKO (human colorectal carcinoma)                                                          Sodium Arsenite                                         MN                        \+        \+              Salazar *et al*. ([@b54-tr-34-311])
  HT-29 (human colon cancer) cells                                                          Sodium Arsenite                                         DNA damage                \+        \+              Stevens *et al*. ([@b53-tr-34-311])
  Human lung adenocarcinoma A549 cells                                                      Arsenic Trioxide and Sodium Arsenite                    Chromosomal breakage/MN   \+        \+              Jiang *et al*. ([@b35-tr-34-311])
  Human hepatocellular carcinoma                                                            Sodium Arsenite                                         DNA damage                \+        \+              Alarifi *et al*. ([@b55-tr-34-311])
  Human hepatocyte L02                                                                      Sodium Arsenite and Arsenic Trioxide                    Chromosomal breakage/MN   \+        \+              Hu *et al*. ([@b36-tr-34-311])
  Human pluripotent stem cells                                                              Arsenic Trioxide                                        DNA damage                \+        \+              Graham *et al*. ([@b56-tr-34-311])
  Primary human bronchial fibroblasts and normal primary human bronchial epithelial cells   Sodium Arsenite                                         CA and DNA damage         \+        \+              Xie *et al*. ([@b57-tr-34-311])

###### 

Inorganic arsenic induced genotoxic effects on human cells *in vivo*

  Test systems                                                                   Arsenic species                                                                 End points          Effects   Dose response   References
  ------------------------------------------------------------------------------ ------------------------------------------------------------------------------- ------------------- --------- --------------- --------------------------------------------------------
  Human lymphocytes                                                              Arsenic in drinking water                                                       CA                  \+        N/A             Petres *et al*. ([@b58-tr-34-311])
  Human lymphocytes                                                              Arsenic in drinking water                                                       CA                  \+        N/A             Beckman *et al*. ([@b63-tr-34-311])
  Human lymphocytes                                                              Arsenic in drinking water                                                       SCE                 \+        N/A             Burgdorf *et al*. ([@b60-tr-34-311])
  Human lymphocytes                                                              Industrial exposure of Sodium Arsenite, Sodium Arsenate from Ronnskar smelter   CA                  \+        N/A             Nordenson *et al*. ([@b59-tr-34-311],[@b64-tr-34-311])
  Human lymphocytes                                                              Psotriatric patients treated with Sodium Arsenite                               SCE                 \+        N/A             Wen *et al*. ([@b39-tr-34-311])
  Human lymphocytes                                                              Arsenic in drinking water                                                       SCE, CA             −         N/A             Vig *et al*. ([@b62-tr-34-311])
  Human lymphocytes                                                              Arsenic in drinking water                                                       CA, MN              \+        N/A             Hu ([@b65-tr-34-311])
  Human lymphocytes                                                              Arsenic in drinking water                                                       CA                  −         N/A             Ostrosky-Wegman *et al*. ([@b61-tr-34-311])
  Human lymphocytes                                                              Arsenic in drinking water                                                       MN                  \+        N/A             Nilsson *et al*. ([@b66-tr-34-311])
  Human lymphocytes                                                              Arsenic in drinking water                                                       SCE                 \+        N/A             Lerda ([@b67-tr-34-311])
  Human lymphocytes                                                              Arsenic in drinking water                                                       MN                  \+        N/A             Warner *et al*. ([@b68-tr-34-311])
  Human lymphocytes                                                              Arsenic in drinking water                                                       SCE, MN             \+        N/A             Dulout *et al*. ([@b69-tr-34-311])
  Human urothelial cells                                                         Arsenic in drinking water                                                       MN                  \+        N/A, +          Moore *et al*. ([@b70-tr-34-311],[@b71-tr-34-311])
  Human urothelial cells                                                         Arsenic in drinking water                                                       MN                            N/A             Biggs *et al*. ([@b72-tr-34-311])
  Human lymphocytes                                                              Arsenic in drinking water                                                       CA, MN              \+        N/A             Gonsebatt *et al*. ([@b73-tr-34-311])
  Human urothelial cells                                                         Arsenic in drinking water                                                       CA                  \+        N/A             Mäki-Paakkanen *et al*. ([@b74-tr-34-311])
  Human urothelial cells                                                         Arsenic in drinking water                                                       CA                  −         N/A             Liou *et al*. ([@b9-tr-34-311])
  Human Buccal mucosal cells, epithelial cells in sputum, and urothelial cells   Arsenic in drinking water                                                       MN                  \+        N/A             Tian *et al*. ([@b25-tr-34-311])
  Buccal mucosa, urothelial cells and Lymphocytes                                Arsenic in drinking water                                                       MN                  \+        N/A             Basu *et al*. ([@b14-tr-34-311],[@b79-tr-34-311])
  Human in lymphocytes                                                           Arsenic in drinking water                                                       DNA Damage          \+        \+              Basu *et al*. ([@b80-tr-34-311])
  Human lymphocytes                                                              Arsenic in drinking water                                                       CA and SCE          \+        N/A             Mahata *et al*. ([@b78-tr-34-311])
  Human lymphocytes from children                                                Arsenic in drinking water                                                       DNA damage          \+        N/A             Yanez *et al*. ([@b81-tr-34-311])
  Human lymphocytes                                                              Arsenic in drinking water                                                       MN                  \+        N/A             Martínez *et al*. ([@b75-tr-34-311])
  Human buccal mucosa cells                                                      Arsenic in drinking water                                                       MN                  \+        N/A             Martínez *et al*. ([@b76-tr-34-311])
  Human lymphocytes, buccal mucosa                                               Arsenic in drinking water                                                       CA, MN              \+        N/A             Ghosh *et al*. ([@b2-tr-34-311],[@b3-tr-34-311])
  Human lymphocytes                                                              Arsenic in drinking water                                                       MN                  \+        N/A             Paiva *et al*. ([@b82-tr-34-311])
  Human urothelial cells                                                         Arsenic in drinking water                                                       MN                  \+        \+              Banerjee *et al*. ([@b7-tr-34-311])
  Human lymphocytes                                                              Arsenic in drinking water                                                       MN and DNA damage   \+        N/A             Sampayo-Reyes *et al*. ([@b77-tr-34-311])
  Human lymphocytes                                                              Arsenic in drinking water                                                       CA                  \+        N/A             Dastgiri *et al*. ([@b83-tr-34-311])
  Buccal mucosa cells from human                                                 Arsenic in drinking water                                                       MN                  \+        N/A             Bartolotta *et al*. ([@b84-tr-34-311])
  Human urothelial cells from children                                           Inorganic Arsenic from soil                                                     MN                  \+        N/A             Gamiño-Gutiérrez *et al*. ([@b85-tr-34-311])
  Human urothelial cells                                                         Arsenic in drinking water                                                       MN                  \+        N/A             Paul *et al*. ([@b21-tr-34-311])
  Buccal mucosa, urothelial cells and Lymphocytes                                Arsenic in drinking water                                                       MN                  \+        N/A             Chatterjee *et al*. ([@b86-tr-34-311])
